The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Rick Body on Twitter re MS.
https://twitter.com/richardbody/status/1338991241686626305?s=19
Rick discussing the Falcon project and testing :
https://s109.podbean.com/pb/9c465b48ecde81a2f10c76181489c56c/5fc16184/data1/fs87/321472/uploads/COVID-19_testing_with_Prof_Rick_Body6dnpv.mp3?pbss=4352408a-4917-5054-a599-3f752b54b70b
6 Tests being evaluated, results in 12 mins, findings coming soon.
A Higgins on Linkdin
https://www.linkedin.com/in/phil-higgins-55742017
Not us, according to the Guardian, it's the Innovs one :
https://www.theguardian.com/world/2020/nov/13/covid-test-for-mass-uk-screening-could-miss-up-to-half-of-cases-say-scientists
The Covid, an unexpected pandemic
The Covid, the desolation of Cummings
The Covid, the Lockdown of the five nations
Lord of the LFTs, The Fellowship of PHE
Lord of the LFTs, The Sensitivity and Specitivity
Lord of the LFTs, The return of normality
Or....
A nightmare before Christmas
Or are there 9 :
https://www.ox.ac.uk/news/2020-11-11-oxford-university-and-phe-confirm-high-sensitivity-lateral-flow-tests-following
SD Biosensor is a nasal swab lft. Details here: https://www.condor-platform.org/files/raptor/covid19-q-ag_en-pdf-data-sheet.pdf
The Condor webpage looks like it was updated yesterday. All of the pages now seem to have content.
From the Falcon page: https://www.condor-platform.org/condor_workstreams/falcon
The results of the new tests will then be compared to the results of the tests that are already being used in clinical practice. The tests that are currently being used in clinical practise use a method called RT- PCR, and we call this the reference method or gold standard. We will then analyse our results to see if the new tests are as accurate as the reference method.
It is likely that we will evaluate approximately 10 new tests in the Falcon study. Many of those tests are likely to be point of care tests, which can be done at the patient's bedside and which often return results in as little as five minutes. We will endeavour to publish our findings in scientific journals. We hope that this work will allow companies to get their new tests to the market faster and will allow patients and the NHS to benefit from the best new testing technologies as soon as we know that it is safe to use them in practice.
From the performance page: https://www.condor-platform.org/condor_workstreams/analytical-performance
The Analytical Performance workstream of CONDOR helps us to evaluate which tests we should try out in the different clinical settings.
This is important, as at the moment lots of tests are being developed to detect SARS-CoV-2, but not all of them will be as good as each other, and we want to make sure we only put the better ones into our clinical studies
The rapid development of tests during the pandemic means that many of them have not had the normal checks/studies to make sure that they are fit for purpose. Not all tests are equal, and we need to make sure that our resources are used wisely - on the better tests.
Manufacturers will make claims about their tests, including how accurate they are; currently these claims may be based on small numbers of samples, leaving room for error in the claims. In addition, we will check that the tests are safe and relatively easy for people to use
Abingdon Health hiring sales managers for the US:
https://www.abingdonhealth.com/wp-content/uploads/2020/09/Contract-Sales-Manager-USA-%E2%80%93-East-Coast-100920.pdf
• Experience in a lateral flow, immunoassay sales environment preferably within an OEM B2B
services capacity
• Familiarity with Antigen and antibody-based assays
LSTM research from June to April on Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis. Recently published.
https://wwwnc.cdc.gov/eid/article/26/11/20-3283_article
Halo test is a RT-PCR lab test using Saliva. Good for Exeter Uni for getting hold of some testing capacity and this is another demonstration that saliva can be used.
https://www.exeter.ac.uk/news/university/title_814623_en.html
Is it better or worse than other PCR and does that matter. Not really competition unless the Gov set up a lab in every institution, post office and off license. Apologies if I am repeating previous posts.
Plagiarised from the ODX board (not a cross ramp)...
The Health Service Journal reported that Ben Davison, an NHS Digital director, had told a board meeting there was a “strategy to scale up to 10 million tests per day”.
The ambition is likely to reflect a desire for more widespread community testing, rather than a programme that relies on people coming forward with symptoms.“
https://www.thetimes.co.uk/article/demand-for-coronavirus-tests-outstripping-supply-han****-admits-lt3lnqhpb
Arizona are rising to the challenge of these uncertain times to provide testing with an FDA EUA-authorized TaqPath COVID-19 assay from Thermofisher Scientific for coronavirus under CLIA certification. We are the first lab in Arizona to use plain saliva samples to identify the presence of COVID-19. Our protocols are readily available for other commercial and academic partners, so they can also adapt their instruments to perform saliva testing.
But the FDA warn.... the test gives false results.
https://www.massdevice.com/fda-warns-on-false-results-for-thermo-fisher-taqpath-covid-19-testing-kit/
Perhaps they should try out Avacta's new kit
Abingdon are recruiting:
1) Lateral Flow Assay Development Scientists
2) Technical Transfer Scientist
3) Group Quality Manager
4) Software Engineer Positions
https://www.abingdonhealth.com/about-us/careers/
I thought this board was about testing not swinging. Mind you, given the ticker and the recent 2 become 1...
Also on the Avacta site this morning:
The Affimer-based ELISA test is capable of detecting the coronavirus spike protein in laboratory samples down to very low concentrations. An evaluation of the ELISA carried out with The Liverpool School of Tropical Medicine using SARS-CoV-2 virus samples shows that it can detect as little as a few thousand virus infectious units per millilitre of sample. This is typical of the levels found in infectious COVID-19 patients’ saliva whether they are symptomatic or not. Highly infectious COVID-19 patients can have many thousands or millions of times more spike protein in their saliva than this.
https://avacta.com/avacta-to-launch-sars-cov-2-elisa-laboratory-test/?utm_content=139272824&utm_medium=social&utm_source=twitter&hss_channel=tw-2279270671
TonyT, yes I agree as per the 22 July bulk sampling update:
As previously announced, the next phase of work over the DGB will involve the surface
trenching of a selection of those 10 new gold targets. Given that the anomalous gold-
in-soil values may indicate elevated gold grades in the underlying strata, the purpose
of the trenching is to remove the soil cover and expose the underlying bedrock and all
quartz outcrops. Eight trenches have been planned in this first phase, each varying in
length from 40-90m for a total of 575m, with each trench being 1m wide and up to 2m
deep. Once exposed, the quartz veining will be sampled, and those samples sent to a
laboratory for assaying.
Upon receipt of planning approval for the surface trenching programme, which is
awaited, the Company intends to carry out this programme in Q4 of this year.